Engineered immune cells take on Hard-to-Treat lung cancer
NCT ID NCT07444281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called C-CAR031 for people with advanced squamous cell lung cancer that has stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to check safety and find the right dose, while also looking for signs that the cancer shrinks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could reveal how lung cancer evolves during treatment
- New drug IDP-001 takes on advanced cancers in early trial
- CRISPR Gene-Edited immune cells aim to fight lung cancer – but trial never started
- New combo therapy aims to boost lung cancer fight
- Custom-Made vaccine takes on tough cancers in early trial
- Experimental combo targets tough lung cancer